related documents
- Decision making factors that influence treatment options for an autologous stem cell transplant for older adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods. Conferences
- Geriatric assessment and frailty changes in older patients with Newly-Diagnosed Multiple Myeloma. Conferences
- Part 1 Results of a dose finding study of Belantamab Mafodotin (GSK2857916) in combination with Pomalidomide (POM) and Dexamethasone (DEX) for the treatment of Relapsed/Refractory Multiple Myeloma Conferences
- Sequential use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Conferences
- Trajectory of symptoms after autologous stem cell transplant among patients with Multiple Myeloma: A Population-Based Study Conferences